Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families


Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases


Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions


Latest News


Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights

Read More

Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference

Read More

Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup

Read More

Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

Read More